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Abstract
Background: A significant minority of dying people experience refractory symptoms or extreme distress
unresponsive to conventional therapies. In such circumstances, sedation may be used to decrease or remove
consciousness until death occurs. This practice is described in a variety of ways, including: ‘palliative sedation’,
‘terminal sedation’, ‘continuous deep sedation until death’, ‘proportionate sedation’ or ‘palliative sedation to
unconsciousness’. Surveys show large unexplained variation in incidence of sedation at the end of life across
countries and care settings and there are ethical concerns about the use, intentions, risks and significance of the
practice in palliative care. There are also questions about how to explain international variation in the use of the
practice. This protocol relates to the UNBIASED study (UK Netherlands Belgium International Sedation Study), which
comprises three linked studies with separate funding sources in the UK, Belgium and the Netherlands. The aims of
the study are to explore decision-making surrounding the application of continuous sedation until death in
contemporary clinical practice, and to understand the experiences of clinical staff and decedents’ informal care-
givers of the use of continuous sedation until death and their perceptions of its contribution to the dying process.
The UNBIASED study is part of the European Association for Palliative Care Research Network.
Methods/Design: To realize the study aims, a two-phase study has been designed. The study settings include: the
domestic home, hospital and expert palliative care sites. Phase 1 consists of: a) focus groups with health care staff
and bereaved informal care-givers; and b) a preliminary case notes review to study the range of sedation therapy
provided at the end of life to cancer patients who died within a 12 week period. Phase 2 employs qualitative
methods to develop 30 patient-centred case studies in each country. These involve interviews with staff and
informal care-givers closely involved in the care of cancer patients who received continuous sedation until death.
Discussion: To our knowledge, this is one of the few studies which seek to take a qualitative perspective on
clinical decision making surrounding the use of continuous sedation until death and the only one which includes
the perspectives of nurses, physicians, as well as bereaved informal care-givers. It has several potential strengths,
weaknesses, opportunities and threats associated with the specific design of the study, as well as with the sensitive
nature of the topic and the different frameworks for ethical review in the participating countries.
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Background
A significant minority (cancer research indicates
between one tenth and one quarter) of dying people
experience refractory symptoms (such as agitated delir-
ium) or extreme distress which is unresponsive to con-
ventional therapies [1,2]. In such circumstances,
sedation may be used to decrease or remove conscious-
ness. Internationally, prevalence studies to ascertain the
percentage of patients receiving sedation for refractory
symptoms at the end of life report variation in use of
between 15% to 60% [3-5]. The wide variation in
reported prevalence is likely to be due in part to differ-
ences in the care setting, patient populations, methods
and the definitions applied. These definitions include:
‘palliative sedation’, ‘terminal sedation’, ‘continuous deep
sedation until death’, ‘proportionate sedation’ and ‘pallia-
tive sedation to unconsciousness’ [6].
One group of studies exists that have enabled compar-
isons to be made; these focus on quantifying types of
medical end of life decisions, using questionnaires to ask
physicians to describe the decision-making and care for
recent deaths they attended [7-9]. One of these studies,
looking at representative samples of death certificates in
six countries in Europe (excluding the UK), employed a
narrow definition of ‘continuous and deep sedation until
death’ to compare physicians’ reports, and showed a
relatively narrow band of variation in prevalence of
between 2.5% to 8.5% of deaths [8]. A survey in the UK
employing the same definition found that 16.5% of the
2,923 respondents reported use of continuous deep
sedation until death, although study limitations may
have led to over estimation of prevalence [7].
An important focus of debate surrounding the practice
concerns the relationship between continuous sedation
until death for refractory symptoms or distress and any
adverse consequences which may result from its use
(known as ‘double effect’ issues) [10]. These include the
risk of paradoxical agitation, the loss of ability of the
patient to interact and the hastening of an expected
death [10-12]. While a systematic review of sedative use
[13] and comparative studies [4,14] have shown no rela-
tionship to exist between the use of sedation for refrac-
tory symptoms or distress and timing of death, in the
Netherlands and Belgium there is evidence to suggest
that continuous sedation until death may sometimes be
used by clinicians both as an alternative for euthanasia
and to hasten an expected death [15,16]. More broadly,
the ethical dimensions of the therapy are increasingly
being debated [17-19].
Ethical concerns surrounding the practice have
resulted in the publication of a number of guidelines or
frameworks for clinical practice [10,20,21]. These
recommend that the use of continuous sedation until
death for refractory symptoms or extreme distress
should occur only when the patient’s disease is irreversi-
ble and advanced, that benzodiazepines should be the
drug of first choice, that decisions to use artificial hydra-
tion should be considered separately and offered to
sedated patients only when the benefits outweigh harm,
and that physicians with little expertise in sedation seek
advice from palliative care specialists before initiating
continuous sedation until death.
There have been calls for research to examine clinical
practice in a qualitative manner to complement the
large scale survey studies described above and provide
explanatory data about the intentions, practices and
understandings associated with continuous sedation
until death and its perceived contribution to the man-
agement of refractory symptoms and distress [22].
There is, with a few exceptions, little research exploring
the understandings, intentions and beliefs of physicians
and nurses regarding the use of continuous sedation
until death or the perceptions and experiences of
bereaved informal care-givers.
Those studies which do exist of health care staff sug-
gest that clinicians, whether physicians or nurses, strug-
gle with the meaning and significance of sedation use in
end of life care [23], are concerned about its possible
link to practices which may end life prematurely [24], or
have objections to the practice on the grounds of reli-
gious belief or moral conviction [25] or because of ideas
about appropriateness of the practice for certain ‘types’
of suffering [26,27]. There is evidence that physicians
and nurses have different experiences of the decision-
making process relating to continuous sedation until
death [28] and of international differences in clinicians’
understandings and perceptions [29]. One small scale
qualitative interview study of clinicians and researchers
in end-of-life care in England, Belgium and the Nether-
lands [30] found that beliefs and attitudes regarding the
practice were affected by the socio-legal context of end-
of-life care practice within each country and that judge-
ments about refractoriness were regarded as likely to be
affected by resource availability.
Studies of bereaved informal care-givers and members
of the general public [31,32] indicate that it is preferable
to provide information in advance about the need to
sedate, its contribution to the care of the patient and its
consequences. One study in Japan shows that one quar-
ter of families who witnessed the use of sedation for
refractory symptoms experienced significant distress
[33].
This protocol relates to the UNBIASED study (UK
Netherlands Belgium International Sedation Study),
which comprises three linked studies with separate
funding sources in the UK, Belgium and the Nether-
lands designed to explore these issues. The UNBIASED
study is part of the European Association for Palliative
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Care Research Network [34]. The study design has been
scientifically peer reviewed as part of the grant applica-
tion process by the Economic and Social Research
Council (UK); Fund for Scientific Research (Belgium),
the Netherlands Organisation for Scientific Research
and the Netherlands Organisation for Health Research
and Development.
Aims of the study
• To explore decision-making surrounding the appli-
cation of continuous sedation until death in contem-
porary clinical practice.
• To understand the experiences of clinical staff and
decedents’ informal care-givers of the use of contin-
uous sedation until death and their perceptions of
its contribution to the dying process.
Research Questions
For cancer patients at home, in hospitals and in hospice
settings:
1. In accounts of clinical practice, what do physi-
cians and nurses mean by sedation in end of life
care?
2. What are the clinical characteristics of the appli-
cation of continuous sedation until death according
to physicians and nurses?
3. How do bereaved informal care-givers, physicians
and nurses describe decedents’ care at the end of life
and the contribution made by continuous sedation
until death?
4. Who are, according to physicians, nurses and
bereaved informal care-givers, the key people
involved in the decision-making with regard to the
use of continuous sedation until death, and what
role do they play?
5. What accounts do physicians and nurses give
about communication and consent in relation to the
use of continuous sedation until death?
6. What reasons are reported for the use of continu-
ous sedation until death by physicians, nurses, and
bereaved informal care-givers, and what reasons for
the use of continuous sedation until death are
described in clinical records and in clinical guide-
lines and protocols?
7. What moral and legal issues emerge from the
accounts of physicians, nurses and bereaved informal
care-givers about decisions taken regarding continu-
ous sedation until death?
8. What aspects of context, attitudes and experience
facilitate or constrain decision-making according to
the accounts of physicians, nurses and bereaved
informal care-givers?
9. What are the differences between Belgium, the
Netherland and the United Kingdom with respect to
the findings of research questions 1 to 8?
Methods/design
Study population
There are four categories within the study population: 1)
deceased adult cancer patients; 2) informal care-givers of
deceased patients; 3) nurses involved; and 4) physicians
Involved in care-giving.
Study settings
The study settings include hospitals, expert palliative
care units and the domestic home.
Design
The UNBIASED study has two phases: an exploratory
phase (1) and a case study phase (2).
Phase 1
Phase 1 of the study has been designed to set the
patient-centred case studies conducted in phase 2 in a
broader context of understanding. It includes a series of
focus groups and case notes review.
Focus groups
In the focus groups, attention is directed at gaining an
understanding of informal care-givers’ and health care
professionals’ beliefs, perceptions, and understandings of
sedation in end-of-life care for adult cancer patients;
and, in the case of health care professionals, also at
gaining an appreciation of their experiences of continu-
ous sedation, and views of the factors that facilitate or
constrain their involvement in its use. Depending on the
context in each participating country, and what data
already exist from earlier work, this has been achieved
by the following means:
a) Focus groups with health care professionals in a
variety of care settings. The UNBIASED study involves
six focus groups with physicians and nurses in the UK
and four in Belgium.
b) Focus groups with informal care-givers. Three focus
groups with informal care-givers have been undertaken
in the Netherlands as part of the UNBIASED
collaboration.
Case notes review
The exploratory phase also includes review in all three
countries of the case notes of adults who have died
from cancer during a given period of 12 weeks in each
of the study settings, i.e. acute hospital care, expert pal-
liative care and domestic home settings. The purpose of
the case notes review is to gain an understanding of the
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prevalence and types of and reasons for sedation therapy
in the end-of-life care of cancer patients.
Phase 2
Phase 2 of the study in all three countries takes the
form of in-depth retrospective case studies of 30 adults
who died from cancer (10 from each type of study set-
ting), where sedation was administered continuously for
otherwise refractory symptoms or distress and was in
place at the time of their death. Case studies have been
found to shed detailed light on problems in palliative
and end-of-life research [35]. They are suitable for
exploring practically and ethically complex situations
involving a variety of perspectives. Detailed insights
from well-constructed case studies also have an explana-
tory potential [36].
Each patient centred case study entails three elements:
a) the reasons for the use of continuous sedation, the
drugs used, and notes about the content of decision-
making, as recorded in the medical notes; b) interviews
with key physicians and nurses involved in the dece-
dent’s care to examine their perspectives on the end of
life management and their role in decision-making; and
c) interviews with bereaved informal care-givers to
explore their recollection and experiences of the dece-
dent’s end of life care.
Inclusion criteria and sample sizes
Phase 1 focus group participants
Nurses and physicians working in hospitals, expert pal-
liative care units or in a community setting, who have
experience of giving care to cancer patients receiving
sedation in the last days of life, and informal care-givers
whose companion received continuous sedation prior to
their death and who died less than one year ago. Care
will be taken to minimise overlap between participation
in the focus groups and the patient-centred case studies
in phase 2 (see below). Sample sizes provided here are
indicative. Sample sizes for nurses and physicians taking
part in focus groups are likely to be up to 30 in each
group. Up to 20 informal care givers are included in
focus groups.
Phase 1 case notes review
The medical and nursing records of all people with a
primary diagnosis of cancer over 18 years old, who died
within a designated 12 week period and were cared for
in participating hospitals, expert palliative care units or
at home. The numbers of case records included in the
search will be dependent upon the number of cancer
deaths occurring within the designated 12 week period.
Phase 2 patient centred case studies
The deceased patients Thirty patients with a primary
diagnosis of cancer over 18 years old, who died in parti-
cipating hospitals, expert palliative care units or at home
(10 patients in each type of setting) and for whom seda-
tion with the intention to decrease awareness was admi-
nistered continuously with sedating medications
(benzodiazepines or propofol, but not morphine) to alle-
viate otherwise uncontrollable symptoms (either physical
or psychological/existential), and for whom the sedation
was in place at the time of death.
Nurses and Physicians Physicians (n = 30) and nurses
(n = 30) who took a key role in the care of the person
who died are invited for interview, within six weeks of
the death. Where more than one clinician was closely
involved, additional interviews may be conducted.
Informal care-givers Individuals (n = 30), over the age
of 18 years who are not professional care-givers but by
default or choice were involved in the care and/or emo-
tional support of the person who died, and who belong
to that person’s immediate social and familial network
[37], are invited to take part in the study at least 3
months following the death.
Study procedure: Phase 1
Case notes review
The case notes review covers a designated 12 week per-
iod. All cancer deaths occurring during this period are
identified by clinical coding used in medical records
departments. Documentary evidence about symptoms,
types and duration of treatment provided and evidence
of end of life decisions during the last week of life are
extracted on a proforma, with particular attention paid
to the use of sedation therapy (see additional file 1).
Focus groups with nurses, physicians and informal care-
givers
Focus groups are held with physicians and nurses who
have experience of working with cancer patients who
have received continuous sedation until death. Similarly,
focus groups are held with informal care-givers whose
relative or friend received continuous sedation until
death in the past year. Discussions take approximately
one hour and are audio recorded and transcribed in full.
Additional files 2 and 3 indicate the areas of discussion
for the focus groups.
Study procedure: Phase 2
Case identification
On a weekly basis, in close collaboration with the
research teams, and using a purposive sampling
approach [38], potential cases of deceased patients who
received continuous sedation for otherwise uncontrolla-
ble symptoms are identified by senior clinical staff work-
ing in the three study sites. This assists in the
identification of a range of cases of interest, where seda-
tion was both planned and unplanned, and with varia-
tion in depth and length of sedative therapy.
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Interviews with key physicians, nurses and informal carers
Invitations are extended to the physicians and nurses
most involved in the care of the deceased patients as
soon as possible, i.e. within six weeks, to maximize
recall. Physicians and nurses are invited to use the
patient records to support them in their recollection of
the case and to provide other relevant information to
the researchers about the case in an anonymous man-
ner. The interviews focus on the nurses’ and physicians’
recollections of the care of the decedent, the interac-
tions with their informal care-givers immediately before
death, and the decision-making process relating to the
use of continuous sedation (see additional file 4). We
seek to uncover the difficulties and problems facing clin-
icians in the practice of continuous sedation until death
and how they sought to resolve them, as well as the
environmental barriers to or facilitators of decisions
made and wider perceptions of death, dying and
bereavement.
At least 3 months after the death of the patient, the
person identified as their closest informal care-giver is
invited to take part in the study via a letter sent on
behalf of the research team by the appropriate senior
clinician. This invitation explains the aims of the
research and sets out the areas covered in the interview.
Individuals are asked to contact the research team if
they are interested in taking part. Telephone contact is
then made to answer questions, explain what involve-
ment in the study will involve and arrange a time and
place for an interview, where this is agreed. Additional
file 5 outlines the interview guide for use in interviews
with bereaved family care-givers, which has been care-
fully designed in recognition of the fact that some care-
givers may not recall the use of sedation therapy.
For all interviews, written informed consent will be
obtained.
Data analysis
Data from the case notes (in the phase 1 case notes
review and phase 2 case studies) is entered into SPSS™
for basic descriptive analysis. With consent from the
participants, the interviews and focus groups are audio
recorded and subsequently transcribed. Transcripts are
analysed with the aid of the qualitative data analysis
package NVIVO™ and using Strauss and Corbin’s [39]
constant comparative method to generate codes, cate-
gories and themes. This involves close collaboration
between the national teams. In relation to the phase 2
case studies, each set of related interviews and case note
reviews will be compiled into a case study. Each tran-
script will be initially analysed by the researcher who
undertook the interview. Emerging categories and
themes will be subsequently verified by another member
of the research team, and then on the basis of
consultation internationally, to enhance validity of the
data. Encrypted anonymised findings from the UK, Bel-
gium and the Netherlands will be shared between the
researchers undertaking this study in parallel in order to
gain a wider international perspective and to subject the
data to an ethical analysis (see next section).
Key themes derived from the cross case analysis and
the international analysis will be presented to clinical
staff from the research sites included in the study and
to audiences of key stakeholders to develop recommen-
dations for practice.
Ethical aspects of the study and ethical analysis of the
data
This study requires that particular sensitivity be shown
when undertaking the interviews. Confidentiality are of
the utmost importance, given the sensitive nature of this
subject. In interviewing bereaved people, we will ensure
that each person is provided with details of local
bereavement support resources. The research inter-
viewer, with the interviewee’s permission, will telephone
them three days after the interview both to check well-
being and to answer any questions which the interview
may have raised. Where the interviewee wishes, contact
will be made with the clinical teams who provided care
to the decedent to help address such questions. Support
and supervision will be provided to the interviewers,
since such fieldwork can cause stress to the research
team. Research ethics committee approval (using the
systems in place in each country) has been sought. In
addition, in the UK it has been necessary to gain
‘research governance’ approval from the organisations
within which each study site is located.
As noted earlier, the data generated by the focus
group discussions as well as the interviews will be sub-
jected to an ethical analysis by the ethicists in the team.
The purpose of this analysis is to provide instruments
that can be used to judge the validity of moral argu-
ments in favour of or against continuous sedation at the
end of life, as well as to distinguish between various
medical practices at the end of life on the basis of
morally relevant criteria (e.g. request by the patient, life-
shortening effect, etc.).
This analysis will inform a broader ethical study of
sedation which is being carried out in parallel with the
empirical study described in this protocol. The over-
arching research question of the ethical study is: under
which conditions is continuous sedation until death
ethically justified? More specifically, based on the
empirical data, the situations in which continuous seda-
tion until death is considered ethically acceptable by
medical practitioners and on what grounds, will be
investigated. The justifications offered will be analysed
with regard to their internal consistency as well as the
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respects in which they differ from ethical justifications
of other medical practices at the end of life.
The various situations, in which continuous sedation
at the end of life is used, will be studied with a focus on
the following criteria:
-Patient autonomy and informed consent:
• Does continuous sedation at the end of life require
informed consent if the patient is competent?
• What about decision making where the patient is
incompetent? Which side constraints should apply
regarding surrogate decision-making?
• What role could advance care planning play in this
context?
-Proportionality of the sedation:
• How should the traditional requirement of propor-
tionality of sedation to the patient’s symptoms be
interpreted and what are its justifications in different
situations?
- The doctrine of double effect and the doctrine of acts
versus omissions:
• To what extent, and under what conditions, does
the practice of continuous sedation until death ‘fit’
with these doctrines;
• Are only intentions relevant in this regard?
• What is the importance of (the lack of) intentions
in cases where the sedation foreseeably results in
shortening the life of the patient?
- Compatibility with legal provisions:
• There seems to be widespread agreement that con-
tinuous sedation until death is part of “normal medi-
cal practice” (like for example, non-treatment
decisions and unlike, for example, euthanasia), but
what about the legal status of cases in which seda-
tion may be used as an alternative to euthanasia or
to life-ending without request?
• Which normative rules ought to apply here?
Discussion
The objectives of the international UNBIASED study are
to explore decision-making surrounding the application
of continuous sedation until death in contemporary clin-
ical practice, and to understand the experiences of clini-
cal staff and decedents’ informal care-givers of the use
of continuous sedation until death and their perceptions
of its contribution to the management of dying. To rea-
lize these objectives, a two-phase qualitative study has
been designed including focus groups and in-depth
interviews; in addition some quantitative data is gath-
ered from clinical records by way of a preliminary case
note review to understand the range of sedation therapy
provided at the end of life to cancer patients who died
within a 12 week period. The first results of the study
are expected in 2011.
This study has several potential strengths, limitations,
opportunities and threats associated with the specific
design of the study, as well as with the sensitive nature
of the topic and these are outlined below.
Strengths
To our knowledge, this is one of the few studies which
seek to take a qualitative perspective on clinical decision-
making surrounding the use of continuous sedation until
death and the only one which includes the perspectives
of nurses, physicians, and bereaved informal care-givers.
Research using qualitative methodologies to provide
understanding about the nuances and challenges of end
of life decision making has featured comparatively rarely
in the medical research literature, although it has a long
tradition in the field of the sociology of health and illness
[40] and, to a lesser but increasing degree, in the study of
bioethics [41]. Our international collaboration brings
together a team of ethicists, sociologists, psychologists,
public health researchers and clinicians (both physicians
and nurses) to lend not only our disciplinary perspectives
to this difficult subject but also to combine what we have
learnt from the application of different methodological
techniques in palliative and end-of-life care research. In
addition, we contribute these from differing national and
cultural contexts, adding a further dimension to the
study which we anticipate will enrich its outcomes.
Limitations
There are a number of limitations to this study, which
stem partly from the sensitivity of the subject and its
relatively small scope, and partly from the methodologi-
cal challenges of studying a phenomenon which is asso-
ciated with such intense debate about its definition,
indications and practice. It is likely that we will have
incomplete data in terms of gathering perspectives from
both professionals and informal care-givers. Moreover,
because this is a qualitative study based on relatively
small numbers of cases, we will not be able to generalise
in a statistical sense from our findings; instead our focus
is primarily on providing contextualised insights on the
basis of case to case transfer and analytical or theoretical
grounds [42]. Perhaps the most challenging and yet the
most interesting aspect concerns matters of definition
and meaning: achieving consensus and thus comparabil-
ity across cases and between national studies is likely to
be difficult given the range of understandings ‘out there’
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about the meaning and appropriateness of sedation in
end-of-life care and the different interpretations of
refractory symptoms and distress [18].
Opportunities
Completion of this project will enable a clinically, ethi-
cally and sociologically informed understanding of some
important but little studied contemporary practices
associated with end-of-life care and contribute to efforts
to develop research methodologies which can capture
the ethical and clinical issues involved in end-of-life care
decision-making at the bedside. We hope that our find-
ings will inform debate and the development of practice
and policy in end-of-life care via collaboration with the
European Association of Palliative Care and other key
national and international stakeholders. The establish-
ment of the UNBIASED research consortium provides
an important opportunity to conduct an international
study of a contentious topic and provides a potential
framework for future collaborations with which research
teams from other counties may wish to engage via
duplication of (parts of) the study.
Threats
The threats to the successful conduct of this study relate
mainly to the differing ethical review frameworks and pro-
cedures encountered in each country. We have had to
make significant adjustments to the study design (espe-
cially in terms of ways of accessing deceased patients’ clin-
ical records) to comply with the strict yet somewhat
different demands imposed by ethical and governance
review committees in the three national contexts. These
procedures specifically apply to researchers not employed
as members of the clinical teams responsible for providing
care to patients included in the study. This risks imposing
additional costs on each national project and has created a
delay in terms of commencement of fieldwork; fortunately
this has been a similar experience in each country. They
also introduce a possibility of bias, because the myriad of
individual requirements imposed by different institutional
review bodies. Considerable and continuing efforts are
therefore necessary to ensure comparability of the national
studies, as the study teams seek to comply with local and
national requirements in the conduct of their projects.
We hope that others will be able to use this protocol
to replicate the study, with necessary local adaptations,
to enable further comparisons.
The international debate on medical decision-making at
the end of life has caused substantial and profound differ-
ences of opinion between opinion leaders, different profes-
sions, the public and different countries. There are now
emerging efforts to facilitate dialogue in spite of these dif-
ferences about how best to collaborate and communicate
in reaching the common goal of better end-of-life care
across Europe. This project will contribute to this by
examining and comparing the issues thrown up by differ-
ent models and approaches to end of life care, and report-
ing these to stakeholders engaged in developing proposals
for policy and practice in this field. This study is one
example of the emergent opportunities for partnerships
between colleagues across a wide span of disciplines to
further the critical and informed debate about a question
that concerns us all: how to shape the compassionate care
of persons in the final stages of life and their companions.
Please contact the lead author for more information
about this study and to discuss any interest in joining
this collaboration.
Additional material
Additional file 1: Box A: Key headings for the case notes review of
adults who died of cancer.
Additional file 2: Box B: Aide memoire for focus group with
physicians and nurses who have experience of sedation therapy.
Additional file 3: Box C: Aide memoire for focus group with
relatives whose relatives experienced sedation therapy.
Additional file 4: Box D: Aide memoire interviews with physicians
and nurses, questions (bold) and subsidiary prompts.
Additional file 5: Box E: Aide memoire interviews with informal
care-givers, questions (bold) and subsidiary prompts.
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